Shanghai-based Tenacia Biotechnology is making a $308 million biobucks move for Rapport Therapeutics' leading asset focused on focal onset seizures (FOS) and primary generalized tonic-clonic seizures, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results